Across a wide range of diseases, repurposing drugs already approved for other indications is a popular strategy, as evidence already exists about their safety and other properties. Significant business model challenges have prevented their widespread development and use, however, how can we better attract private capital to accelerate these ideas through the commercialization process? What types of compounds are most amenable to policy efforts that might help change this landscape?

Moderator

Mike Rea

CEO, IDEA Pharma

Speakers

Howard Fillit

Co-Founder and Chief Science Officer, Alzheimer's Drug Discovery Foundation

Sandi Heibel

Chief Operating Officer, Audacity Therapeutics

Ethan Perlstein

CEO, Perlara

Heather Stone

Health Science Policy Analyst, US Food and Drug Administration